Metraipolis › archive › dc_73939d30451d

Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study — Europe PMC PMID:42827135

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42827135
DOI
10.1038/s41408-[numero omesso]-1
License (as archived)
solo-consultazione
Archived
2026-10-08T05:17:15.842Z
SHA-256 of the archived text
ae7596ef8c789afe9fde78c3aef629c61fdf21f70699bb27a3bffb085d5f0b10
Stable URL of this page
https://metraipolis.com/documento/dc_73939d30451d

How to cite

Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study — Europe PMC PMID:42827135 — Europe PMC (en), https://europepmc.org/article/MED/42827135 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_73939d30451d (Metraipolis archive dc_73939d30451d, sha256 ae7596ef8c789afe9fde78c3aef629c61fdf21f70699bb27a3bffb085d5f0b10)
BibTeX
@misc{dc73939d30451d,
  title = {Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study — Europe PMC PMID:42827135},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42827135},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_73939d30451d; sha256 ae7596ef8c789afe9fde78c3aef629c61fdf21f70699bb27a3bffb085d5f0b10},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42827135. Agents can read the archived copy with the MCP tool read_document.